Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Bella, Nisenbaum"'
Autor:
Daniel Reinhorn, Maya Gottfried, Michal Sarfaty, Judit Prus, Hadar Goldvaser, Tzipora Shohat, Rinat Yerushalmi, Shlomit Yust-Katz, Olga Ulitsky, Irina Kuchuk, Daniel Hendler, Victoria Neiman, Bella Nisenbaum, Ofer Rotem, Dalia Zoref
Publikováno v:
Cancer Research. 80:P1-18
Background Combination of pertuzumab, trastuzumab and chemotherapy is standard of care for first-line treatment of patients with human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer. Most randomized studies used combinati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0351826c68c227ee8db089fc21daff5
https://doi.org/10.1158/1538-7445.sabcs19-p1-18-33
https://doi.org/10.1158/1538-7445.sabcs19-p1-18-33
Autor:
Maya Gottfried, Tzippy Shochat, V. Neiman, Daniel Reinhorn, Daliah Tsoref, Ofer Rotem, Judit Prus, Olga Olitzky, Shlomit Yust-Katz, Bella Nisenbaum, Aaron Sulkes, Daniel Hendler, Michal Sarfaty, Rinat Yerushalmi, Iryna Kuchuk, Hadar Goldvaser
Publikováno v:
Breast Cancer Research and Treatment.
The combination of a taxane with trastuzumab and pertuzumab is standard of care for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. The combination of vinorelbine with trastuzumab and pertuzu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed694efdd9ce7dd63c15e2235581b33c
https://doi.org/10.1007/s10549-021-06198-4
https://doi.org/10.1007/s10549-021-06198-4
Autor:
Daniel, Reinhorn, Iryna, Kuchuk, Tzippy, Shochat, Bella, Nisenbaum, Aaron, Sulkes, Daniel, Hendler, Ofer, Rotem, Daliah, Tsoref, Olga, Olitzky, Hadar, Goldvaser, Michal, Sarfaty, Victoria, Neiman, Judit, Prus, Maya, Gottfried, Shlomit, Yust-Katz, Rinat, Yerushalmi
Publikováno v:
Breast cancer research and treatment. 188(2)
The combination of a taxane with trastuzumab and pertuzumab is standard of care for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. The combination of vinorelbine with trastuzumab and pertuzu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ab039fe713cb46638eb8f66cdc50f73c
https://pubmed.ncbi.nlm.nih.gov/33772709
https://pubmed.ncbi.nlm.nih.gov/33772709
Autor:
Rinat Yerushalmi, Bella Nisenbaum, Larisa Ryvo, Noa Efrat, Ella Evron, Tamar Safra, Luna Kadouri, Bella Kaufman
Publikováno v:
Clinical Breast Cancer. 18:e197-e203
Purpose In the Breast cancer trials of OraL EveROlimus-2 (BOLERO-2) trial, everolimus plus exemestane improved progression-free survival (PFS) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b92673f6c3a4d0732ab15bc129f30736
https://doi.org/10.1016/j.clbc.2017.09.004
https://doi.org/10.1016/j.clbc.2017.09.004
Autor:
Shulamith Rizel, S.M. Stemmer, Tamar Peretz, Ora Rosengarten, Larisa Ryvo, Nicky Liebermann, Georgeta Fried, Christer Svedman, Lior Soussan-Gutman, N Ben Baruch, Avital Bareket-Samish, Bella Nisenbaum, David B. Geffen, Debbie McCullough, Mariana Steiner
Publikováno v:
Cancer Research. 78:P1-07
Background: The 21-gene Recurrence Score (RS) Assay (Oncotype DX®) is a validated prognosticator and predictive of chemotherapy (CT) benefit in patients with hormone receptor (HR)+ human epidermal growth factor receptor 2 (HER2)-negative breast canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3aaacdc34817b707ce34ed7ab2f4a1b3
https://doi.org/10.1158/1538-7445.sabcs17-p1-07-14
https://doi.org/10.1158/1538-7445.sabcs17-p1-07-14
Autor:
Steven Shak, Ora Rosengarten, Shulamith Rizel, Bella Nisenbaum, Christer Svedman, Noa Ben-Baruch, Mariana Steiner, Lior Soussan-Gutman, Salomon M. Stemmer, Georgeta Fried, Nicky Liebermann, David B. Geffen, Tamar Peretz, Debbie McCullough, Kevin Isaacs, Avital Bareket-Samish
Publikováno v:
npj Breast Cancer, Vol 3, Iss 1, Pp 1-7 (2017)
NPJ Breast Cancer
NPJ Breast Cancer
The Recurrence Score® is increasingly used in node-positive ER+ HER2-negative breast cancer. This retrospective analysis of a prospectively designed registry evaluated treatments/outcomes in node-positive breast cancer patients who were Recurrence S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d44130fe4ed6019c5f58498e0fd5ac2
http://link.springer.com/article/10.1038/s41523-017-0033-7
http://link.springer.com/article/10.1038/s41523-017-0033-7
Autor:
Shulamith Rizel, Michelle Leviov, Debbie M Jakubowski, David B. Geffen, Ora Rosengarten, Mariana Steiner, Steven Shak, Avital Bareket-Samish, Noa Ben-Baruch, Margarita Tokar, Amit Itay, Daniela Katz, Julie Baron, Nicky Liebermann, Salomon M. Stemmer, Lior Soussan-Gutman, Beatrice Uziely, Bella Nisenbaum, Georgeta Fried
Publikováno v:
npj Breast Cancer, Vol 5, Iss 1, Pp 1-6 (2019)
NPJ Breast Cancer
NPJ Breast Cancer
The 21-gene Recurrence Score (RS) assay is a validated prognosticator/predictor of chemotherapy (CT) benefit in early-stage estrogen receptor (ER)-positive breast cancer (BC). Long-term data from real-life clinical practice where treatment was guided
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4728233c9753d3200b2717aab0399ebf
https://doi.org/10.1038/s41523-019-0137-3
https://doi.org/10.1038/s41523-019-0137-3
Autor:
Alexandru Eniu, Günther G. Steger, Thomas Brodowicz, Bohuslav Melichar, Christoph C. Zielinski, Salomon M. Stemmer, Richard Greil, Zsuzsanna Kahán, Zanete Zvirbule, Daniela Sirbu, Tadeusz Pienkowski, Semir Beslija, Bella Nisenbaum, Rodica Anghel, Diethelm Messinger, M. Dank, Lubos Petruzelka, István Láng, Moshe Inbar
Publikováno v:
The Lancet Oncology. 17:1230-1239
Summary Background The randomised phase 3 TURANDOT trial compared two approved bevacizumab-containing regimens for HER2-negative metastatic breast cancer in terms of efficacy, safety, and quality of life. The interim analysis did not confirm non-infe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76f45836fc9c3d8b26bf99e10d1eafb7
https://doi.org/10.1016/s1470-2045(16)30154-1
https://doi.org/10.1016/s1470-2045(16)30154-1
Autor:
Ella Evron, Lior Soussan-Gutman, Bella Nisenbaum, Beatrice Uziely, Ora Rosengarten, Larisa Ryvo, Salomon M. Stemmer, S. Rizel, Nicky Liebermann, Steven Shak, David B. Geffen, Mariana Steiner, Bella Kaufman, Megan P. Rothney, J. Zidan, Georgeta Fried, Christer Svedman, Noa Ben-Baruch, Kevin Isaacs, S. Klang
Publikováno v:
Cancer Research. 76:P5-08
Background: The 21-Gene Recurrence Score® Assay (Oncotype DX®) has been validated as a prognostic and predictive tool in estrogen receptor (ER)+ breast cancer in multiple studies using archival specimens of clinical trials with long term follow up.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e7f203974a5da11b0a04aa025590649
https://doi.org/10.1158/1538-7445.sabcs15-p5-08-02
https://doi.org/10.1158/1538-7445.sabcs15-p5-08-02
Autor:
Miguel Gil, Cynthia Huang Bartlett, Bella Nisenbaum, Maribel Casas, Mireia Margeli Vila, Begoña Bermejo, Claire Swift, Laura Murillo Jaso, Eva Ciruelos, Miguel Martin, Christoph C. Zielinski, István Láng, Eva Carrasco, Massimo Corsaro, Montserrat Muñoz, Antonio Antón, Manuel Ruiz-Borrego, Nuria Martin, Maria Koehler, Nicholas C. Turner
Publikováno v:
Journal of Clinical Oncology. 38:1022-1022
1022 Background: Prior retrospective data has shown ESR1 mutation is an acquired resistant mechanism to AI. However, little is known about ist prognostic and predictive value to endocrine-based therapy and chemotherapy. PEARL study compared PAL+ET vs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44201f65768539953edafe6d37b727b8
https://doi.org/10.1200/jco.2020.38.15_suppl.1022
https://doi.org/10.1200/jco.2020.38.15_suppl.1022